The role of NH4Cl and cysteine proteases in human papillomavirus type 16 infection

Virology Journal

Volumn 6, Issue , 2009, Pages

  Dabydeen, Sarah A ^a   Meneses, Patricio I ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM CHLORIDE; CATHEPSIN B; FURIN; ANTIVIRUS AGENT; CYSTEINE PROTEINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; VERRUCA VULGARIS; VIRUS PARTICLE; ANIMAL; CELL CULTURE; CELL LINE; DRUG EFFECT; ENDOSOME; HOST PATHOGEN INTERACTION; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; VIROLOGY; VIRUS ENTRY;

HUMAN PAPILLOMAVIRUS TYPE 16; JC POLYOMAVIRUS; MIRIDAE;

AMMONIUM CHLORIDE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; ENDOSOMES; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, KNOCKOUT; VIRUS INTERNALIZATION;

EID: 68749122026     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-109     Document Type: Article

References (40)

1. Invasion of host cells by JC virus identifies a novel role for caveolae in endosomal sorting of noncaveolar ligands. W Querbes BA O'Hara G Williams WJ Atwood, J Virol 2006 80 9402 9413 16973546 10.1128/JVI.01086-06 (Pubitemid 44435619)
2. Papillomaviruses infect cells via a clathrin-dependent pathway. PM Day DR Lowy JT Schiller, Virology 2003 307 1 11 10.1016/S0042-6822(02)00143-5 12667809 (Pubitemid 36355861)
3. Bovine papillomavirus type 1: from clathrin to caveolin. V Laniosz KA Holthusen PI Meneses, J Virol 2008 82 6288 6298 18417596 10.1128/JVI.00569-08 (Pubitemid 351875108)
4. Human Papillomavirus Type 16 Infection of Human Keratinocytes Requires Clathrin, Caveolin-1, and is Brefeldin A-Sensitive. V Laniosz SA Dabydeen MA Havens PI Meneses, J Virol 2009 19494002
5. Case-control study of human papillomavirus and oropharyngeal cancer. G D'Souza AR Kreimer R Viscidi M Pawlita C Fakhry WM Koch WH Westra ML Gillison, N Engl J Med 2007 356 1944 1956 10.1056/NEJMoa065497 17494927 (Pubitemid 46740304)
6. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. CE Greer CM Wheeler MB Ladner K Beutner MY Coyne H Liang A Langenberg TS Yen R Ralston, J Clin Microbiol 1995 33 2058 2063 7559948
7. Human papillomavirus infections of the genital and respiratory tracts in young children. SH Sinal CR Woods, Semin Pediatr Infect Dis 2005 16 306 316 10.1053/j.spid.2005.06.010 16210110 (Pubitemid 41422334)
8. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. TS Baker WW Newcomb NH Olson LM Cowsert C Olson JC Brown, Biophys J 1991 60 1445 1456 1663794 10.1016/S0006-3495(91)82181-6
9. Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. J Doorbar PH Gallimore, J Virol 1987 61 2793 2799 3039170
10. Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. BL Trus RB Roden HL Greenstone M Vrhel JT Schiller FP Booy, Nat Struct Biol 1997 4 413 420 10.1038/nsb0597-413 9145113
11. Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. I Bossis RB Roden R Gambhira R Yang M Tagaya PM Howley PI Meneses, J Virol 2005 79 6723 6731 15890910 10.1128/JVI.79.11.6723- 6731.2005 (Pubitemid 40677303)
12. The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. A Fay WHt Yutzy RB Roden J Moroianu, J Virol 2004 78 13447 13454 15564455 10.1128/JVI.78.24.13447-13454.2004 (Pubitemid 39612744)
13. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. SC Holmgren NA Patterson MA Ozbun PF Lambert, J Virol 2005 79 3938 3948 15767396 10.1128/JVI.79.7.3938-3948.2005 (Pubitemid 40388334)
14. Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18. V Laniosz KC Nguyen PI Meneses, J Virol 2007 81 7435 7448 17475643 10.1128/JVI.00571-07 (Pubitemid 47047832)
15. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Zhou DJ Stenzel XY Sun IH Frazer, J Gen Virol 1993 74 Pt 4 763 768 10.1099/0022-1317-74-4-763 8385700
16. Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. L Bousarghin A Touze AL Combita-Rojas P Coursaget, J Gen Virol 2003 84 157 164 10.1099/vir.0.18789-0 12533712 (Pubitemid 36113561)
17. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. JG Joyce JS Tung CT Przysiecki JC Cook ED Lehman JA Sands KU Jansen PM Keller, J Biol Chem 1999 274 5810 5822 10.1074/jbc.274.9.5810 10026203 (Pubitemid 29109237)
18. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. S Shafti-Keramat A Handisurya E Kriehuber G Meneguzzi K Slupetzky R Kirnbauer, J Virol 2003 77 13125 13135 14645569 10.1128/JVI.77.24. 13125-13135.2003 (Pubitemid 37494308)
19. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. M Evander IH Frazer E Payne YM Qi K Hengst NA McMillan, J Virol 1997 71 2449 2456 9032382
20. alpha6 integrin is not the obligatory cell receptor for bovine papillomavirus type 4. G Sibbet C Romero-Graillet G Meneguzzi M Saveria Campo, J Gen Virol 2000 81 Pt 6 1629 10811948
21. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. L Bousarghin A Touze PY Sizaret P Coursaget, J Virol 2003 77 3846 3850 12610160 10.1128/JVI.77.6.3846-3850.2003 (Pubitemid 36297304)
22. Papillomavirus capsid binding and uptake by cells from different tissues and species. M Muller L Gissmann RJ Cristiano XY Sun IH Frazer AB Jenson A Alonso H Zentgraf J Zhou, J Virol 1995 69 948 954 7815562
23. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. N Kamper PM Day T Nowak HC Selinka L Florin J Bolscher L Hilbig JT Schiller M Sapp, J Virol 2006 80 759 768 16378978 10.1128/JVI.80.2.759-768.2006 (Pubitemid 43062888)
24. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. RM Richards DR Lowy JT Schiller PM Day, Proc Natl Acad Sci USA 2006 103 1522 1527 16432208 10.1073/pnas.0508815103 (Pubitemid 43191198)
25. Cysteine cathepsins: multifunctional enzymes in cancer. MM Mohamed BF Sloane, Nat Rev Cancer 2006 6 764 775 10.1038/nrc1949 16990854 (Pubitemid 44450465)
26. Transcriptional induction of Smurf2 ubiquitin ligase by TGF-beta. N Ohashi T Yamamoto C Uchida A Togawa H Fukasawa Y Fujigaki S Suzuki K Kitagawa T Hattori T Oda, FEBS Lett 2005 579 2557 2563 10.1016/j.febslet.2005.03.069 15862290 (Pubitemid 40615658)
27. Mutant K-ras regulates cathepsin B localization on the surface of human colorectal carcinoma cells. D Cavallo-Medved J Dosescu BE Linebaugh M Sameni D Rudy BF Sloane, Neoplasia 2003 5 507 519 14965444
28. Glycosaminoglycans facilitate procathepsin B activation through disruption of propeptide-mature enzyme interactions. D Caglic JR Pungercar G Pejler V Turk B Turk, J Biol Chem 2007 282 33076 33085 10.1074/jbc.M705761200 17726009 (Pubitemid 350159276)
29. Inhibitor studies indicate that active cathepsin L is probably essential to its own processing in cultured fibroblasts. A Salminen MM Gottesman, Biochem J 1990 272 39 44 2264836
30. Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. K Ishidoh E Kominami, Biochem Biophys Res Commun 1995 217 624 631 10.1006/bbrc.1995.2820 7503744 (Pubitemid 26011756)
31. Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. RL Kaletsky G Simmons P Bates, J Virol 2007 81 13378 13384 17928356 10.1128/JVI.01170-07 (Pubitemid 350247834)
32. A mature and fusogenic form of the Nipah virus fusion protein requires proteolytic processing by cathepsin L. CT Pager WW Craft Jr J Patch RE Dutch, Virology 2006 346 251 257 10.1016/j.virol.2006.01.007 16460775 (Pubitemid 43357869)
33. Cathepsin L is involved in proteolytic processing of the Hendra virus fusion protein. CT Pager RE Dutch, J Virol 2005 79 12714 12720 16188974 10.1128/JVI.79.20.12714-12720.2005 (Pubitemid 41433191)
34. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. IC Huang BJ Bosch F Li W Li KH Lee S Ghiran N Vasilieva TS Dermody SC Harrison PR Dormitzer, J Biol Chem 2006 281 3198 3203 10.1074/jbc.M508381200 16339146 (Pubitemid 43845930)
35. Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry. Z Qiu ST Hingley G Simmons C Yu J Das Sarma P Bates SR Weiss, J Virol 2006 80 5768 5776 16731916 10.1128/JVI.00442-06 (Pubitemid 43849155)
36. Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. DH Ebert J Deussing C Peters TS Dermody, J Biol Chem 2002 277 24609 24617 10.1074/jbc.M201107200 11986312 (Pubitemid 34951989)
37. Maturation of papillomavirus capsids. CB Buck CD Thompson YY Pang DR Lowy JT Schiller, J Virol 2005 79 2839 2846 15709003 10.1128/JVI.79.5.2839-2846.2005 (Pubitemid 40270562)
38. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. L Pelkmans J Kartenbeck A Helenius, Nat Cell Biol 2001 3 473 483 10.1038/35074539 11331875 (Pubitemid 32422083)
39. Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. JL Smith SK Campos MA Ozbun, J Virol 2007 81 9922 9931 17626097 10.1128/JVI.00988-07 (Pubitemid 350067695)
40. Clathrin- and caveolin-independent entry of human papillomavirus type 16 involvement of tetraspanin-enriched microdomains (TEMs). G Spoden K Freitag M Husmann K Boller M Sapp C Lambert L Florin, PLoS ONE 2008 3 e3313 18836553 10.1371/journal.pone.0003313